Literature DB >> 1845770

Virus-specific cytotoxic lymphocyte response in a neurotropic murine leukemia virus infection.

D S Robbins1, P M Hoffman.   

Abstract

NFS/N mice infected with neurotropic Cas-Br-M murine leukemia virus (MuLV) at 21 days of age were resistant to neurologic disease and demonstrated MuLV-specific cytotoxic T lymphocyte (CTL) activity in spleen cells after in vitro stimulation. NFS/N mice infected with Cas-Br-M MuLV at 2 days of age failed to generate a significant MuLV-specific CTL response and developed neurologic disease 5-8 weeks later. Protection from neurologic disease transferred with fewer in vitro stimulated immune spleen cells than immune T cells from NFS/N mice infected with Cas-Br-M MuLV at 21 days of age. Cas-Br-M MuLV-specific CTL may play an important role in resistance to the paralytic effects of Cas-Br-M MuLV infection by affecting virus dissemination to the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845770     DOI: 10.1016/0165-5728(91)90081-h

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  Immunogenic determinants of a neuropathogenic murine leukemia virus.

Authors:  D S Robbins; M P Remington; M Sarzotti; D St Louis; P M Hoffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Age-dependent resistance to murine retrovirus-induced spongiform neurodegeneration results from central nervous system-specific restriction of virus replication.

Authors:  M Czub; S Czub; F J McAtee; J L Portis
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  Murine retrovirus-induced spongiform encephalomyelopathy: host and viral factors which determine the length of the incubation period.

Authors:  M Czub; F J McAtee; J L Portis
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 4.  T cell immunity in neonates.

Authors:  A M Garcia; S A Fadel; S Cao; M Sarzotti
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.